Michael C. Cameron

1.4k total citations · 1 hit paper
36 papers, 948 citations indexed

About

Michael C. Cameron is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Michael C. Cameron has authored 36 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Dermatology, 8 papers in Immunology and Allergy and 7 papers in Physiology. Recurrent topics in Michael C. Cameron's work include Dermatology and Skin Diseases (18 papers), Allergic Rhinitis and Sensitization (8 papers) and Asthma and respiratory diseases (7 papers). Michael C. Cameron is often cited by papers focused on Dermatology and Skin Diseases (18 papers), Allergic Rhinitis and Sensitization (8 papers) and Asthma and respiratory diseases (7 papers). Michael C. Cameron collaborates with scholars based in United States, United Kingdom and Germany. Michael C. Cameron's co-authors include Anthony Rossi, Miguel Córdova, Shoko Mori, Kishwer S. Nehal, Brian P. Hibler, Erica Lee, Christopher A. Barker, Marco DiBonaventura, Jeremy J. Midgley and William J. Bond and has published in prestigious journals such as The Journal of Comparative Neurology, Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology.

In The Last Decade

Michael C. Cameron

33 papers receiving 925 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Basal cell carcinoma

2018 297 citations Michael C. Cameron, Erica Lee et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael C. Cameron United States	13	538	358	195	182	158	36	948
Jérôme Lamartine France	20	187 0.3×	144 0.4×	238 1.2×	54 0.3×	750 4.7×	44	1.3k
Tomo Suzuki Japan	26	464 0.9×	50 0.1×	26 0.1×	176 1.0×	154 1.0×	59	2.4k
Satoko Shimizu Japan	18	105 0.2×	211 0.6×	187 1.0×	18 0.1×	406 2.6×	67	1.2k
J. Wayne Streilein United States	20	188 0.3×	103 0.3×	71 0.4×	111 0.6×	186 1.2×	33	1.5k
Sara Peters United States	14	121 0.2×	158 0.4×	310 1.6×	14 0.1×	420 2.7×	50	1.1k
Masahiro Morimoto Japan	18	49 0.1×	117 0.3×	135 0.7×	69 0.4×	261 1.7×	85	955
Bernard G. Gross United States	15	438 0.8×	114 0.3×	121 0.6×	37 0.2×	296 1.9×	17	968
F D'Hermiès France	20	146 0.3×	208 0.6×	125 0.6×	12 0.1×	306 1.9×	132	1.4k
Winkelmann Rk United States	18	316 0.6×	302 0.8×	101 0.5×	23 0.1×	154 1.0×	71	1.0k
Kanna Ramaesh United Kingdom	23	152 0.3×	67 0.2×	25 0.1×	105 0.6×	242 1.5×	79	2.0k

Countries citing papers authored by Michael C. Cameron

Since Specialization

Citations

This map shows the geographic impact of Michael C. Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Cameron more than expected).

Fields of papers citing papers by Michael C. Cameron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Cameron. The network helps show where Michael C. Cameron may publish in the future.

Co-authorship network of co-authors of Michael C. Cameron

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Cameron. A scholar is included among the top collaborators of Michael C. Cameron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Cameron. Michael C. Cameron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Issa, Naiem T., Linda Stein Gold, Emma Guttman‐Yassky, et al.. (2025). Patients With a Smoking History and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer). SKIN The Journal of Cutaneous Medicine. 9(6). s614–s614.

Boh, Erin, Michael C. Cameron, Brad Glick, et al.. (2025). A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel. Journal of Drugs in Dermatology. 24(2). 147–155.

Desai, Seemal R., Linda Stein Gold, Michael C. Cameron, et al.. (2023). Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials. Dermatology and Therapy. 13(10). 2443–2460. 5 indexed citations

Shi, Vivian Y., Tina Bhutani, Luz Fonacier, et al.. (2022). Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). Journal of the American Academy of Dermatology. 87(2). 351–358. 54 indexed citations

Ständer, Sonja, Shawn G. Kwatra, Jonathan I. Silverberg, et al.. (2022). Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial. American Journal of Clinical Dermatology. 24(1). 97–107. 14 indexed citations

Reich, Kristian, Peter Lio, Robert Bissonnette, et al.. (2022). Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology In Practice. 10(12). 3228–3237.e2. 9 indexed citations

Blauvelt, Andrew, Mark Boguniewicz, Patrick M. Brunner, et al.. (2022). Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. Journal of Dermatological Treatment. 33(5). 2605–2613. 2 indexed citations

Silverberg, Jonathan I., Jacob P. Thyssen, Kyle Fahrbach, et al.. (2021). Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 35(9). 1797–1810. 86 indexed citations

Kim, Brian, Jonathan I. Silverberg, Sonja Ständer, et al.. (2021). Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies. Dermatitis. 32(1S). S39–S44. 11 indexed citations

10.

Gooderham, Melinda, Chia‐Yu Chu, Ricardo Rojo, et al.. (2021). Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE. JAAD International. 4. 46–48. 9 indexed citations

11.

Lio, Peter, Mark Boguniewicz, Andrew Alexis, et al.. (2021). Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE. Journal of Allergy and Clinical Immunology. 147(2). AB34–AB34. 1 indexed citations

12.

Blauvelt, Andrew, Jonathan I. Silverberg, Charles Lynde, et al.. (2021). Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. Journal of the American Academy of Dermatology. 86(1). 104–112. 89 indexed citations

13.

Salem, Islam Elbayoumi, Mauricio Retuerto, Michael C. Cameron, et al.. (2020). 362 Psoriatic fungal and bacterial microbiomes identify patient endotypes. Journal of Investigative Dermatology. 140(7). S45–S45. 1 indexed citations

14.

Simpson, Eric L., Sonja Ständer, Gil Yosipovitch, et al.. (2020). 16346 Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial. Journal of the American Academy of Dermatology. 83(6). AB61–AB61. 2 indexed citations

15.

Cameron, Michael C., Erica Lee, Brian P. Hibler, et al.. (2018). Basal cell carcinoma. Journal of the American Academy of Dermatology. 80(2). 303–317. 297 indexed citations breakdown →

16.

Cameron, Michael C., Erica Lee, Brian P. Hibler, et al.. (2018). Basal cell carcinoma. Journal of the American Academy of Dermatology. 80(2). 321–339. 101 indexed citations

17.

Cameron, Michael C., Andrea Suárez, Mark G. Kris, & Patricia L. Myskowski. (2018). Inflamed Actinic Keratoses After Pemetrexed.. PubMed. 14(6). 473–474. 1 indexed citations

18.

Cameron, Michael C. & Anthony Rossi. (2016). Reflectance Confocal Microscopy for Skin Cancer Margins: How it Works. Current Dermatology Reports. 5(3). 172–178. 2 indexed citations

19.

Cameron, Michael C., et al.. (2014). Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatology Online Journal. 20(11). 15 indexed citations

20.

Cameron, Michael C., Ren‐Zhi Zhan, & J. Victor Nadler. (2011). Morphologic integration of hilar ectopic granule cells into dentate gyrus circuitry in the pilocarpine model of temporal lobe epilepsy. The Journal of Comparative Neurology. 519(11). 2175–2192. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact